Cargando…

On-chip manufacturing of synthetic proteins for point-of-care therapeutics

Therapeutic proteins have recently received increasing attention because of their clinical potential. Currently, most therapeutic proteins are produced on a large scale using various cell culture systems. However, storing and transporting these therapeutic proteins at low temperatures makes their di...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Travis W., Sheng, Jiayuan, Naler, Lynette B., Feng, Xueyang, Lu, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431678/
https://www.ncbi.nlm.nih.gov/pubmed/31057940
http://dx.doi.org/10.1038/s41378-019-0051-8
_version_ 1783405970119983104
author Murphy, Travis W.
Sheng, Jiayuan
Naler, Lynette B.
Feng, Xueyang
Lu, Chang
author_facet Murphy, Travis W.
Sheng, Jiayuan
Naler, Lynette B.
Feng, Xueyang
Lu, Chang
author_sort Murphy, Travis W.
collection PubMed
description Therapeutic proteins have recently received increasing attention because of their clinical potential. Currently, most therapeutic proteins are produced on a large scale using various cell culture systems. However, storing and transporting these therapeutic proteins at low temperatures makes their distribution expensive and problematic, especially for applications in remote locations. To this end, an emerging solution is to use point-of-care technologies that enable immediate and accessible protein production at or near the patient’s bedside. Here we present the development of “Therapeutics-On-a-Chip (TOC)”, an integrated microfluidic platform that enables point-of-care synthesis and purification of therapeutic proteins. We used fresh and lyophilized materials for cell-free synthesis of therapeutic proteins on microfluidic chips and applied immunoprecipitation for highly efficient, on-chip protein purification. We first demonstrated this approach by expressing and purifying a reporter protein, green fluorescent protein. Next, we used TOC to produce cecropin B, an antimicrobial peptide that is widely used to control biofilm-associated diseases. We successfully synthesized and purified cecropin B at 63 ng/μl within 6 h with a 92% purity, followed by confirming its antimicrobial functionality using a growth inhibition assay. Our TOC technology provides a new platform for point-of-care production of therapeutic proteins at a clinically relevant quantity.
format Online
Article
Text
id pubmed-6431678
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-64316782019-05-03 On-chip manufacturing of synthetic proteins for point-of-care therapeutics Murphy, Travis W. Sheng, Jiayuan Naler, Lynette B. Feng, Xueyang Lu, Chang Microsyst Nanoeng Article Therapeutic proteins have recently received increasing attention because of their clinical potential. Currently, most therapeutic proteins are produced on a large scale using various cell culture systems. However, storing and transporting these therapeutic proteins at low temperatures makes their distribution expensive and problematic, especially for applications in remote locations. To this end, an emerging solution is to use point-of-care technologies that enable immediate and accessible protein production at or near the patient’s bedside. Here we present the development of “Therapeutics-On-a-Chip (TOC)”, an integrated microfluidic platform that enables point-of-care synthesis and purification of therapeutic proteins. We used fresh and lyophilized materials for cell-free synthesis of therapeutic proteins on microfluidic chips and applied immunoprecipitation for highly efficient, on-chip protein purification. We first demonstrated this approach by expressing and purifying a reporter protein, green fluorescent protein. Next, we used TOC to produce cecropin B, an antimicrobial peptide that is widely used to control biofilm-associated diseases. We successfully synthesized and purified cecropin B at 63 ng/μl within 6 h with a 92% purity, followed by confirming its antimicrobial functionality using a growth inhibition assay. Our TOC technology provides a new platform for point-of-care production of therapeutic proteins at a clinically relevant quantity. Nature Publishing Group UK 2019-03-25 /pmc/articles/PMC6431678/ /pubmed/31057940 http://dx.doi.org/10.1038/s41378-019-0051-8 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Murphy, Travis W.
Sheng, Jiayuan
Naler, Lynette B.
Feng, Xueyang
Lu, Chang
On-chip manufacturing of synthetic proteins for point-of-care therapeutics
title On-chip manufacturing of synthetic proteins for point-of-care therapeutics
title_full On-chip manufacturing of synthetic proteins for point-of-care therapeutics
title_fullStr On-chip manufacturing of synthetic proteins for point-of-care therapeutics
title_full_unstemmed On-chip manufacturing of synthetic proteins for point-of-care therapeutics
title_short On-chip manufacturing of synthetic proteins for point-of-care therapeutics
title_sort on-chip manufacturing of synthetic proteins for point-of-care therapeutics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431678/
https://www.ncbi.nlm.nih.gov/pubmed/31057940
http://dx.doi.org/10.1038/s41378-019-0051-8
work_keys_str_mv AT murphytravisw onchipmanufacturingofsyntheticproteinsforpointofcaretherapeutics
AT shengjiayuan onchipmanufacturingofsyntheticproteinsforpointofcaretherapeutics
AT nalerlynetteb onchipmanufacturingofsyntheticproteinsforpointofcaretherapeutics
AT fengxueyang onchipmanufacturingofsyntheticproteinsforpointofcaretherapeutics
AT luchang onchipmanufacturingofsyntheticproteinsforpointofcaretherapeutics